Natrol 5-HTP 100 mg Time Release Review

Not without your prescriber's explicit sign-off. Time-release changes the speed of release, not the pharmacology: 5-HTP is a direct serotonin precursor, and combined with an SSRI, SNRI, MAOI, triptan, tramadol, or other serotonergic drug it can cause serotonin syndrome — a serious and occasionally life-threatening reaction. Memorial Sloan Kettering and US Poison Control warn against the combination, and Drugs.com flags 5-HTP + SSRIs as 'major.' If you take any antidepressant or have a medical condition, clear 5-HTP with your doctor before using it at all.

No — and it's worth being precise about. Time-release means the tablet is designed to dissolve and release the 5-HTP gradually over time, smoothing out the dose. Enteric coating is different: it's a coating designed to survive stomach acid and release the dose lower in the GI tract, which is specifically aimed at reducing stomach upset. This Natrol product is time-release, not enteric-coated, so it still releases in the stomach. If your concern is nausea, the genuinely enteric-coated Solaray (#6) is the targeted pick; if you just like a gradual release, time-release is the appeal here.

It's cheap because Natrol is a high-volume mass-market brand and 5-HTP is close to a commodity — not because anything's wrong with it. At roughly $0.14 per tablet across 90 tablets, it's the lowest entry price on the list. The trade-offs are the things you'd expect at that price: it's a tablet with binders rather than a capsule, there are no B6/C cofactors, and the testing is in-house rather than independently certified. For a low-commitment first try, that's a reasonable bargain, not a warning sign.

One tablet daily, with food to reduce the chance of nausea. Many people take 5-HTP in the evening because serotonin is the precursor to melatonin, and the time-release format is sometimes marketed with sleep in mind — but it also works for daytime mood or appetite support. Whatever the timing, start with a single 100 mg tablet and give it a few weeks before judging. Don't stack it higher without understanding the serotonergic-drug safety caveat first.

Honestly, the evidence is real but modest. The best mood data is Shaw 2002, a Cochrane review (PMID 12169147), which found a benefit signal over placebo but flagged that only 2 of 108 studies were high-quality. There isn't a strong stand-alone human sleep RCT we'd hang our hat on — the sleep angle is mechanistic (serotonin is the precursor to melatonin), so treat it as plausible rather than proven. The appetite/weight data (Cangiano 1992/1998) is more consistent but from small studies. Reasonable low-cost experiment; not a guaranteed fix.

1. [1] Shaw 2002 (Cochrane) PMID 12169147 — Tryptophan and 5-hydroxytryptophan for depression. Of 108 studies on 5-HTP/tryptophan for depression, only 2 met the quality bar; pooled they favored 5-HTP/tryptophan over placebo, but the authors stressed the evidence was insufficient. The honest anchor for the mood claim.
2. [2] Cangiano 1992 PMID 1384305 — Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Double-blind RCT, 20 obese subjects, 5-HTP 900 mg/day: significant weight loss, reduced carbohydrate intake, early satiety. Behind the appetite/weight use case — small study, high dose.
3. [3] Cangiano 1998 PMID 9705024 — Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. In overweight NIDDM patients, oral 5-HTP decreased energy intake and produced weight loss. Reinforces the appetite/satiety mechanism in a second small clinical population.